Tetrahydrocannabinol

Phase 2Small molecule

HHadassah Medical Organization

Tetrahydrocannabinol is one of 151 small molecule programs targeting Chronic Pancreatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PancreatitisActive, not recruiting

Abdominal PainActive, not recruiting

MemoryActive, not recruiting

OsteoarthritisActive, not recruiting

FibromyalgiaActive, not recruiting

Chronic PancreatitisPhase 2

Active, not recruiting

Abdominal PainPhase 2

Active, not recruiting

MemoryPreclinical

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

FibromyalgiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Tetrahydrocannabinol

HHadassah Medical Organization

Phase 2

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Toradol

Roche

Preclinical

1 5

Bayer Aspirin

Bayer

Preclinical

—6

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 7

Glucophage

Boehringer Ingelheim

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Osteoarthritis

NCT04992624

Q3 2027

Phase 2Recruiting

Sleep

NCT05269628

Q4 2027

Phase 1Recruiting

Study completion

NCT06772753

Q4 2030

Phase 1/2Not yet recruiting

Cannabis

NCT06381180

Clinical

Trials by Indication[1]

Fibromyalgia1 trial

Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia

Unknown status·HHadassah Medical Organization·N/A·NCT01149018·80 enrolled

Premedication1 trial

Anesthetic Premedication With a Cannabis Extract (Cannapremed)

Unknown status·HHadassah Medical Organization·Phase 2/3·NCT02283281·200 enrolled

Chronic Pancreatitis1 trial

Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

Completed·RRadboud University Medical Center·Phase 2·NCT01551511·29 enrolled

Function1 trial

Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

Completed·—·N/A·NCT02291536·20 enrolled

Post-Traumatic Stress Disorder1 trial

Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)

Unknown status·HHadassah Medical Organization·Phase 4·NCT00965809·70 enrolled

8 more indications

Osteoarthritis1 trial

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Recruiting·SSteven E Harte, PhD·Phase 2·NCT04992624·200 enrolled

Sleep1 trial

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Recruiting·—·Phase 2·NCT05269628·166 enrolled

Cannabis Use1 trial

The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults

Recruiting·SSobereye Inc.·N/A·NCT06967051·20 enrolled

Abdominal pain1 trial

The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain

Completed·RRadboud University Medical Center·Phase 2·NCT01562483·36 enrolled

Cannabis1 trial

Warrior CARE: Cannabis Behavioral Health

Not yet recruiting·WWayne State University·Phase 1/2·NCT06381180·500 enrolled

Marijuana1 trial

Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2

Completed·WWayne State University··NCT00218504·20 enrolled

Memory1 trial

Effects of THC and CBD on Human Episodic Memory Function

Completed·—·N/A·NCT02291562·20 enrolled

Unspecified2 trials

Investigation of Psychedelic Effects in Psychoactive Substances

Recruiting·JJohns Hopkins University·Phase 1·NCT06772753·50 enrolled

The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

Completed·WWageningen University·N/A·NCT02112292·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Tetrahydrocannabinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetrahydrocannabinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetrahydrocannabinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hadassah Medical Organization company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHadassah Medical Organization

Tetrahydrocannabinol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q4 2030

Trials by Indication[1]

Fibromyalgia1 trial

Premedication1 trial

Chronic Pancreatitis1 trial

Function1 trial

Post-Traumatic Stress Disorder1 trial

Osteoarthritis1 trial

Sleep1 trial

Cannabis Use1 trial

Abdominal pain1 trial

Cannabis1 trial

Marijuana1 trial

Memory1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News